Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma
Human H-ferritin (HFn), regorafenib (REGO), and Cu2+ were rationally designed as a brain-targeted nanoplatform, fulfilling the task of site-specific delivery and manipulating autophagy and cuproptosis against glioblastoma multiforme.
[Prostate Cancer Foundation] The Prostate Cancer Foundation announced four inaugural Class of 2022 TACTICAL Award recipients. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer.
[Nature Communications] Researchers reported high levels of androgen receptor chromatin binding heterogeneity in human primary prostate tumors, that overlapped with heterogeneity observed in healthy prostate epithelium.